Last updated: April 5, 2026
What Is Diglycerin and Its Role in the Pharmaceutical Industry?
Diglycerin, also known as diglycerol or 1,2,3-propanetriol, is a glycerol derivative used as an excipient in pharmaceutical formulations. It acts primarily as a humectant and plasticizer, ensuring stability, moisture retention, and improved texture in drug products. Its non-toxic nature and solubility make it suitable for oral, topical, and injectable formulations.
Market Size and Growth Drivers
Current Market Size
The global pharmaceutical excipients market was valued at approximately USD 8.4 billion in 2021. Diglycerin’s market share remains modest, estimated between 2% and 3%, owing to its niche application status. Based on these proportions, the Diglycerin segment generated roughly USD 168 million to USD 252 million in 2021.
Growth Trajectory
The overall pharmaceutical excipient market is projected to grow at a compound annual growth rate (CAGR) of 5.5% from 2022 to 2027.[1] Drivers include:
- Expansion of biologics and complex formulations requiring specialized excipients
- Rising demand for water-soluble and non-toxic excipients
- Increasing regulatory approvals for excipients derived from renewable sources
Given its niche positioning, Diglycerin’s annual growth rate is estimated slightly above 5%, aligning with the broader market trend but influenced by specific regulatory and supply factors.
Supply Chain and Manufacturing Trends
Production Sources
Diglycerin is produced through glycerol esterification or glycerol dehydration processes. Major producers include:
- Brenntag
- Tokyo Chemical Industry Co.
- Fenchem Biotek
- Stepan Company
Production is concentrated in Asia (China, India), North America, and Europe. Supply chain disruptions, such as pandemic-induced logistics issues, have temporarily constricted availability and impacted pricing.
Raw Material and Cost Dynamics
Glycerol, the precursor, is often sourced as a byproduct of biodiesel manufacturing, influencing feedstock prices. Fluctuations in biodiesel demand directly impact glycerol prices, thereby affecting diglycerin costs.
Regulatory Landscape
Regulatory bodies, such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA), approve diglycerin as a GRAS (Generally Recognized as Safe) substance. Changes or updates in excipient guidelines influence manufacturing practices and formulation development timelines.
Competitive Landscape and Innovation Trends
Major Manufacturers
The market is segmented among a handful of prominent suppliers, with domestically focused producers in Asia competing with established Western chemical giants. Innovation centers on:
- Enhanced purity grades (e.g., pharmaceutical-grade diglycerin)
- Bio-based and sustainable sourcing
- Custom-grade formulations tailored for specific delivery systems
Patent and Regulatory Filings
While no critical patents cover diglycerin as an excipient, ongoing regulatory scrutiny impacts formulation diversity. Companies investing in excipient development seek regulatory fast-tracks via streamlined submissions for approved grades.
Financial Trajectory and Investment Outlook
Revenue Projections
Based on current market estimates, diglycerin as an excipient could see revenues reach approximately USD 250 million to USD 350 million by 2027, if compounded annually at 5–6%. Growth is driven by:
- Expanding biologic formulations
- Rising demand for non-toxic excipients
- Regulatory approval of new formulations
R&D and Market Penetration
Pharmaceutical firms and excipient developers allocate between 5-7% of revenue to R&D initiatives. A focus on bio-based, stable, and multifunctional excipients aims to increase diglycerin’s application scope, supporting incremental revenue growth.
Risks and Challenges
- Supply chain vulnerabilities
- Regulatory delays or reinspections
- Competition from alternative excipients with similar functionalities
Key Takeaways
- Diglycerin’s niche status limits its market share but benefits from the broader excipient market growth.
- The compound’s non-toxic, water-soluble properties align with trends toward safer, more sustainable excipients.
- Market expansion depends on supply chain stability, ongoing regulatory compliance, and innovation in formulation use cases.
- Estimated revenues are projected by 2027 to reach USD 250–350 million with a CAGR of approximately 5–6%.
FAQs
How does diglycerin compare to other glycerol derivatives in the pharmaceutical sector?
Diglycerin offers a balance of non-toxicity, moisture retention, and plasticizing properties that match or surpass other derivatives like mono- or triglycerides. Unlike triglycerides, it is water-soluble and suitable for aqueous formulations.
Which pharmaceutical applications most commonly utilize diglycerin?
It is used in topical creams, oral suspensions, and injectable formulations that require humectants and stabilizers. Its plasticizing property improves texture in transdermal patches.
What regulatory hurdles affect the use of diglycerin as an excipient?
While approved as GRAS in the U.S., the European Union classifies its use under specific additive regulations. Formulation-specific approvals are required when used in novel dosage forms or higher concentrations.
What emerging trends could influence diglycerin’s market growth?
Increased focus on bio-based, sustainable excipients favors diglycerin. Development of multifunctional excipients combining plasticizer and humectant functions enhances its value proposition.
What are the main competitive advantages of diglycerin over synthetic alternatives?
Its non-toxic profile, approval status, and compatibility with sensitive formulations position it favorably against synthetic, petroleum-based excipients.
References
[1] MarketsandMarkets. (2022). Pharmaceutical Excipients Market by Type, Source, Function, and Region: Global Forecast to 2027.
